The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | Main takeaways from WCLC 2022
Benjamin Besse, MD, Gustave Roussy Institute, Villejuif, France, elaborates on his main takeaways from WCLC 2022. He discusses encouraging results from the Phase I GDC-6036 study, which reported that the patient response rate to the GDC-6036 drug is good, however the progression-free survival (PFS) response is yet to be measured. Prof. Besse also briefly discusses data from the HUDSON trial (NCT03334617) for treatment-resistant patients with advanced non-small cell lung cancer (NSCLC) and touches upon results from a study comparing tumor lesions, which found that limited resections were a viable treatment option compared to a lobectomy. Perioperative immunotherapy, a novel treatment option for resectable NSCLC, is mentioned as an important field that, although promising, requires further exploration. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
